Emmaus Life Sciences Q3 2025 Earnings Report

Emmaus Life Sciences EPS Results

• Actual EPS: -$0.03
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Emmaus Life Sciences Revenue Results

• Actual Revenue: $3.38 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Emmaus Life Sciences Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: During Market Hours
• Conference Call Date: N/A
• Conference Call Time: N/A

Emmaus Life Sciences (OTCMKTS:EMMA) is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other serious medical conditions. The company’s best-known product is Endari (L-glutamine) oral powder, which was approved by the U.S. Food and Drug Administration in 2017 to reduce acute complications associated with sickle cell disease in adults and children aged five and older.

Emmaus has also pursued research programs involving metabolic, gastrointestinal and other rare disorders, including therapies intended to address conditions with limited treatment options. Its activities have included product development, regulatory submissions and commercialization efforts in the United States and selected international markets.

The company was founded by physician and researcher Yutaka Niihara, who has served as its chief executive officer and has been closely associated with its sickle cell disease program. Information about Emmaus’ current operations, product portfolio and leadership may change as the company’s business develops.